Sharemaestro Newsreel

IDEXX Laboratories Inc Stock Price Live, Charts & News

This article provides live stock information for IDEXX Laboratories Inc (IDXX), including its current share price, historical performance, and key financial metrics like market capitalization, PE ratio, and dividend yield. It also presents the company's balance sheet, income statement, and cash flow data up …

TWIST BIOSCIENCE CORP : LEERINK PARTNERS RAISES TARGET PRICE $120.00 FROM $110.00

Leerink Partners has raised its target price for Twist Bioscience Corp (TWST.O) from $110.00 to $120.00. This indicates an increased positive outlook from the analytical firm regarding the company's future stock performance.

NTRA 2-DAY DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Natera, Inc. (NTRA) Investors with Losses to Contact Firm's Attorneys Before June 27th Deadline in Securities Class Action

Hagens Berman, National Trial Attorneys, is urging investors of Natera, Inc. (NTRA) who have suffered significant losses to contact their attorneys before the June 27th deadline for a securities class action lawsuit. The lawsuit alleges that Natera misrepresented the reliability and superiority of its …

GeneDx Holdings (WGS) Is Up 9.7% After Beating Q2 Estimates And Reaffirming 2026 Outlook - Has The Bull Case Changed?

FULGENT GENETICS INC : PIPER SANDLER RAISES TARGET PRICE TO $19.00 FROM $15.00

Piper Sandler has raised its target price for Fulgent Genetics Inc (FLGT.O) shares to $19.00 from $15.00. This update indicates a more optimistic outlook from the analyst firm regarding the company's future stock performance. The report was issued by Reuters on August 4, 2026.

Fulgent Genetics Inc (7F0) Q1 2024 Earnings Report - Results, Call & Slides

Fulgent Genetics Inc (7F0) has released its Q1 2024 earnings report, showing an actual EPS of -€0.01, beating the consensus EPS of -€0.28. The company's revenue for the quarter was €55.93M, missing the expected €56.69M, and showing a YoY revenue growth decline of 2.54%. …

Icon earnings on deck amid accounting probe uncertainty

ICON PLC is set to release its long-delayed full-year 2025 results on March 9, amidst an internal accounting investigation that has significantly impacted its market value. Analysts anticipate earnings of $3.31 per share on revenue of $2.01 billion, with the probe primarily focusing on …

BTIG raises Castle Biosciences stock price target on strong revenue

BTIG has increased its price target for Castle Biosciences (CSTL) to $44 from $40, maintaining a Buy rating, citing the company's strong 20% revenue beat and 20% growth. This performance was primarily driven by the TissueCypher franchise, with significant volume increases. Despite the stock …

Veracyte (VCYT) Is Down 18.2% After Raising 2026 Revenue Guidance on New Cancer Tests

Veracyte (VCYT) shares dropped 18.2% despite the company raising its full-year 2026 revenue guidance to US$590 million to US$596 million, up from a previous range, following strong Q2 results of US$150.32 million revenue and US$25.49 million net income. This improved outlook is attributed to …

Illumina Inc (ILMN) volume expands as weekly chart confirms a 44.6% 12-week climb

The diagnostics-and-research stock closed the week higher, with trading activity above its recent average and Market Dynamics showing confirmation.

Guardant Health Price Target Raised to $180.00/Share From $130.00 by Stifel

Stifel has raised its price target for Guardant Health (NASDAQ:GH) from $130.00 to $180.00 per share. This indicates a significant increase in the analyst's valuation of the company's stock.

BLLN Company (NASDAQ: BLLN) insider plans sale of 2,500 Class A shares

An insider at BLLN Company (NASDAQ: BLLN) plans to sell 2,500 Class A shares on August 3, 2026, via NASDAQ, with an aggregate value of $343,425.00. These shares were originally acquired as Pre-IPO Shares on December 30, 2021. The notice also reveals previous sales …

Form 4 Adaptive Biotechnologies Corp For: 3 August By Investing.com

This article from Investing.com announces the filing of Form 4 for Adaptive Biotechnologies Corp on August 3rd. Form 4 is a document filed with the SEC to report changes in beneficial ownership of a company's securities by insiders. The article includes the stock symbol …

Biodesix Inc expected to post a loss of 90 cents a share - Earnings Preview

Biodesix Inc is projected to report a loss of 90 cents per share. This information comes from a Refinitiv earnings preview. The full article is available on TradingView, which aggregates news from various sources including Reuters.

Adaptive Biotechnologies (NASDAQ: ADPT) CCO trades 1,299 shares under plan

Adaptive Biotechnologies Corp's Chief Commercial Officer, Susan Bobulsky, sold 1,299 shares of common stock on July 30, 2026, at $24.00 per share, totaling $31,176. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025. Following the sale, Bobulsky …

DeepHealth Receives FDA 510(k) Clearance for AI-Driven Breast Ultrasound Automation

DeepHealth, a subsidiary of RadNet, has received FDA 510(k) clearance for its AI-driven Breast Ultrasound platform. This technology automates lesion detection, ACR BI-RADS characterization, and reporting, aiming to standardize breast ultrasound examinations and improve cancer detection. RadNet plans to deploy this platform across its …

Form 144 Mettler-Toledo International Inc. For: 3 August By Investing.com

The article is a Form 144 filing for Mettler-Toledo International Inc. for August 3rd, published by Investing.com. It primarily serves as a placeholder or announcement for the regulatory filing, with minimal actual content beyond the title and date. The piece also includes stock performance …

Twist Bioscience Jumps as Raised 2026 Outlook Appears to Drive Buying

Twist Bioscience (TWST) stock jumped 10.4% following its fiscal third-quarter update, which included a raised full-year 2026 revenue outlook and continued progress toward adjusted EBITDA breakeven. The company increased its revenue guidance to $456 million-$457 million and highlighted improving execution in its synthetic biology …

Mettler-Toledo appoints Natalia Shuman to board of directors

Mettler-Toledo International Inc. has announced the appointment of Natalia Shuman to its board of directors, effective immediately. Shuman currently serves as president and CEO of MISTRAS Group and has extensive leadership experience in global organizations providing testing, inspection, and certification services. Her background aligns …

Natera (NTRA) insider Solomon Moshkevich files to sell 12,720 shares

Solomon Moshkevich, an insider at Natera (NTRA), has filed a Form 144 to sell up to 12,720 shares of common stock, with a proposed sale date on or after July 31, 2026. These shares were acquired as Restricted Stock Units on January 31, 2025, …

Natera (NTRA) insider Jonathan Sheena plans 108-share sale after recent trades

Jonathan Sheena, an insider at Natera, Inc. (NTRA), has filed a notice to sell 108 shares of common stock valued at $28,918.08, with the proposed sale date set for August 3, 2026. The filing also reveals that Sheena holds 3,549 Restricted Stock Units granted …

Illumina, Inc. (ILMN) legal chief sells 615 shares in planned trade

Illumina's Chief Legal Officer, Scott M. Davies, sold 615 shares of common stock on July 30, 2026, at a price of $200.00 per share. This transaction, executed under a Rule 10b5-1 trading plan, leaves him with 20,338 shares directly owned. The sale, valued at …

[10-Q] GeneDx Holdings Corp. Quarterly Earnings Report

GeneDx Holdings Corp. (WGS) filed its quarterly earnings report (Form 10-Q) for the period ended June 30, 2026. The report details a new financing structure involving an amended loan agreement for an additional $50 million, increasing debt capacity to $150 million, and a conditional …

IQV (NYSE: IQV) holder files to sell 5,500 common shares under Rule 144

A shareholder of IQVIA HOLDINGS INC. (NYSE: IQV) has filed a Form 144 notice indicating their intent to sell 5,500 shares of common stock. The aggregate market value of these shares is $1,279,740.00, with the proposed sale date set for August 3, 2026, on …

IDEXX Laboratories (IDXX) director granted 49 deferred stock units

IDEXX Laboratories director Joseph L. Hooley acquired 49 deferred stock units on July 30, 2026, under the company's Director Deferred Compensation Plan. These units, valued at $27,280.22 based on a closing share price of $558.80, vest immediately and will be paid in stock after …

Agilent Technologies Inc. stock rises Monday, still underperforms market

Agilent Technologies Inc. stock (A) rose 1.03% on Monday, closing at $139.80, breaking a three-day losing streak. Despite the gain, the stock underperformed the broader market, as the S&P 500 Index (SPX) increased by 1.48% and the Dow Jones Industrial Average (DJIA) rose by …

Danaher's Rainer Blair to Retire; Julie Sawyer Montgomery Starts Oct. 1

Danaher (NYSE: DHR) has announced that Julie Sawyer Montgomery will become its new President and Chief Executive Officer, effective October 1, 2026. She will succeed Rainer Blair, who is retiring and will serve as a senior advisor during the transition period. Montgomery has been …

Natera (NTRA) holder John Fesko plans Rule 144 sale after prior stock disposals

John Fesko, a shareholder of Natera, Inc. (NTRA), has filed a Rule 144 notice to sell 292 common shares valued at $78,185.92 on NASDAQ, effective August 3, 2026. This planned sale follows four previous open-market disposals of Natera common stock by Fesko in the …

Danaher stock rises after naming new CEO, backing guidance

Danaher Corporation's shares rose 2% after hours following the announcement of Julie Sawyer Montgomery as the new President and CEO, effective October 1, 2026. The company also reaffirmed its previously communicated financial guidance for the third quarter and full year 2026. Montgomery, who has …

Danaher Corp. stock rises Monday, still underperforms market

Shares of Danaher Corp. (DHR) increased by 1.29% on Monday, closing at $197.50, despite the broader market also seeing gains with the S&P 500 up 1.48% and the Dow Jones Industrial Average up 1.32%. This rise for Danaher snapped a three-day losing streak, though …

Twist Bioscience (TWST) insider Paula Green files to sell 1,133 shares

Twist Bioscience insider Paula Green has filed a Form 144 to sell 1,133 shares of common stock through Fidelity Brokerage Services LLC on August 3, 2026. These shares are linked to restricted stock vesting on July 31, 2026, as compensation. The filing also details …

Thermo Fisher Continues Skyline Center Lease, Plans For Long-term 'solution'

Thermo Fisher Scientific has renewed its lease for two years at downtown Wilmington's Skyline Center, where it occupies over 57,000 square feet. The company, which acquired PPD in 2021, is committed to its Wilmington operations beyond 2028 and is seeking a "longer-term solution" to …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Medpace Holdings, Inc. (MEDP) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Medpace Holdings, Inc. (NASDAQ:MEDP) who bought securities prior to April 22, 2025, and still hold them. The investigation aims to determine if Medpace and its officers engaged in corporate wrongdoing. …

Mettler-Toledo International, Inc. Stock 12‑Month Price Target Raised to $1495.8, Implies 6% Upside

Mettler-Toledo International, Inc.'s average stock price target has been raised to $1495.8 from $1478.3, according to estimates from 10 analysts. This updated target suggests a potential 6% upside based on the July 31 closing price. The consensus rating among 15 analysts remains a "Buy," …

Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN)

Levi & Korsinsky, LLP has announced an investigation into Myriad Genetics (NASDAQ: MYGN) after the company significantly cut its full-year 2026 revenue guidance and suspended adjusted EBITDA guidance. This comes just three months after reaffirming higher revenue projections, leading to investor losses. The firm …

Twist Bioscience Reports 12.0% Wider Q3 2026 Loss at -$0.56/Share

Twist Bioscience (NASDAQ:TWST) reported a wider-than-expected Q3 2026 diluted loss of $0.56 per share, missing analyst estimates despite achieving robust revenue growth of 23.3% to $118.4 million. The company's net loss reached $35.1 million due to continued investments in capacity expansion and market penetration. …